{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:30Z","timestamp":1760239830311,"version":"build-2065373602"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.iac.2023.04.009","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T06:55:41Z","timestamp":1685861741000},"page":"723-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms"],"prefix":"10.1016","volume":"43","author":[{"given":"Tsewang","family":"Tashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.iac.2023.04.009_bib2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.iac.2023.04.009_bib3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12288-020-01279-8","article-title":"The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis","volume":"36","author":"Helbig","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"12","key":"10.1016\/j.iac.2023.04.009_bib4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.iac.2023.04.009_bib6","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.iac.2023.04.009_bib7","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.21.01849","article-title":"Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis","volume":"40","author":"Lubke","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.iac.2023.04.009_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/17474086.2021.1959315","article-title":"Avapritinib for Systemic Mastocytosis","volume":"14","author":"Bose","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"15","key":"10.1016\/j.iac.2023.04.009_bib9","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1182\/blood.2021014612","article-title":"Avapritinib for advanced systemic mastocytosis","volume":"140","author":"Gotlib","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.iac.2023.04.009_bib10","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.iac.2023.04.009_bib11","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.iac.2023.04.009_bib12","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1182\/bloodadvances.2022007539","article-title":"Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis","volume":"6","author":"Reiter","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.iac.2023.04.009_bib13","series-title":"Normal healthy volunteers","first-page":"81","article-title":"Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor","author":"Dave","year":"2021"},{"issue":"140","key":"10.1016\/j.iac.2023.04.009_bib14","first-page":"1","article-title":"Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)","author":"DeAngelo","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cell.2007.05.055","article-title":"Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor","volume":"130","author":"Yuzawa","year":"2007","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.iac.2023.04.009_bib17","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2023.04.009_bib18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.iac.2023.04.009_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebiom.2019.03.089","article-title":"Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis","volume":"43","author":"Grootens","year":"2019","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.iac.2023.04.009_bib20","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.iac.2023.04.009_bib21","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2023.04.009_bib22","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.iac.2023.04.009_bib23","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3109\/10428194.2011.647314","article-title":"Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia","volume":"53","author":"Kristensen","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.iac.2023.04.009_bib24","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00277-022-04897-6","article-title":"Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation","volume":"101","author":"Yin","year":"2022","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.leukres.2006.03.006","article-title":"Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone","volume":"31","author":"Pullarkat","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.iac.2023.04.009_bib26","first-page":"27","article-title":"Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia","volume":"2","author":"Pullarkat","year":"2009","journal-title":"J\u00a0Hematop"},{"issue":"11","key":"10.1016\/j.iac.2023.04.009_bib27","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.leukres.2012.07.001","article-title":"Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis","volume":"36","author":"Cornet","year":"2012","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00277-012-1580-5","article-title":"KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1\/RUNX1T1 rearrangement","volume":"92","author":"Kim","year":"2013","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.iac.2023.04.009_bib29","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00277-017-3074-y","article-title":"D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations","volume":"96","author":"Yui","year":"2017","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.iac.2023.04.009_bib30","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2023.04.009_bib31","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.ejca.2013.04.005","article-title":"Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13","volume":"49","author":"Bachet","year":"2013","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.iac.2023.04.009_bib32","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1182\/blood-2005-02-0583","article-title":"Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate","volume":"106","author":"Cammenga","year":"2005","journal-title":"Blood"},{"issue":"5350","key":"10.1016\/j.iac.2023.04.009_bib33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.iac.2023.04.009_bib34","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.iac.2023.04.009_bib35","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management","volume":"7","author":"Castells","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.iac.2023.04.009_bib36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.iac.2023.04.009_bib37","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2023.04.009_bib38","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.iac.2023.04.009_bib39","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.iac.2023.04.009_bib40","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","article-title":"Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis","volume":"64","author":"Greiner","year":"2018","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"10.1016\/j.iac.2023.04.009_bib42","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.iac.2023.04.009_bib43","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1365-2362.2009.02184.x","article-title":"Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology","volume":"39","author":"Sperr","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.iac.2023.04.009_bib44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2023.04.009_bib46","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","article-title":"The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome","volume":"8","author":"Butterfield","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.iac.2023.04.009_bib47","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.iac.2023.04.009_bib48","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.iac.2023.04.009_bib49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0145-2126(03)00065-1","article-title":"Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia","volume":"27","author":"Pardanani","year":"2003","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.iac.2023.04.009_bib50","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/bcj.2014.94","article-title":"Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia","volume":"5","author":"Lasho","year":"2015","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.iac.2023.04.009_bib51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.iac.2023.04.009_bib52","article-title":"Mast Cell Leukemia: Clinical and Molecular Features and Survival Outcomes of Patients in the ECNM Registry","author":"Kennedy","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.iac.2023.04.009_bib53","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.iac.2023.04.009_bib54","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2023.04.009_bib55","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.iac.2023.04.009_bib56","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/bjh.17932","article-title":"Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases","volume":"196","author":"Tefferi","year":"2022","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.iac.2023.04.009_bib57","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iac.2023.04.009_bib58","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol Rev"},{"issue":"11","key":"10.1016\/j.iac.2023.04.009_bib59","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"issue":"9383","key":"10.1016\/j.iac.2023.04.009_bib61","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.iac.2023.04.009_bib62","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2023.04.009_bib63","doi-asserted-by":"crossref","first-page":"e1002068","DOI":"10.1371\/journal.pcbi.1002068","article-title":"Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms","volume":"7","author":"Laine","year":"2011","journal-title":"PLoS Comput Biol"},{"issue":"40","key":"10.1016\/j.iac.2023.04.009_bib64","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.iac.2023.04.009_bib65","first-page":"17","article-title":"PKC412--a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro","year":"2000","journal-title":"Anti Cancer Drug Des"},{"issue":"414","key":"10.1016\/j.iac.2023.04.009_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A\u00a0precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.iac.2023.04.009_bib67","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1002\/onco.13674","article-title":"Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy","volume":"26","author":"George","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.iac.2023.04.009_bib68","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1182\/blood-2022-167410","article-title":"AZURE: A Phase 1\/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis. Abstract","volume":"140","author":"DeAngelo","year":"2022","journal-title":"Blood"},{"issue":"138","key":"10.1016\/j.iac.2023.04.009_bib69","first-page":"1","article-title":"Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance. Abstract","author":"Guarnieri","year":"2021","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.iac.2023.04.009_bib70","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/bloodadvances.2019000152","article-title":"A\u00a0phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis","volume":"3","author":"Gotlib","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.iac.2023.04.009_bib71","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"issue":"138","key":"10.1016\/j.iac.2023.04.009_bib72","first-page":"1","article-title":"Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study. Abstract","author":"Deininger","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2023.04.009_bib73","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/bloodadvances.2020003980","article-title":"Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing","volume":"5","author":"Lim","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.iac.2023.04.009_bib74","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.iac.2023.04.009_bib75","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.iac.2023.04.009_bib76","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.iac.2023.04.009_bib77","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.iac.2023.04.009_bib78","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2023.04.009_bib79","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.iac.2023.04.009_bib80","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Munoz-Gonzalez","year":"2018","journal-title":"Blood Adv"},{"issue":"31","key":"10.1016\/j.iac.2023.04.009_bib81","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.iac.2023.04.009_bib82","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/bloodadvances.2018026245","article-title":"Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models","volume":"2","author":"Pardanani","year":"2018","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.iac.2023.04.009_bib83","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.iac.2023.04.009_bib84","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.iac.2023.04.009_bib85","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/j.jaip.2022.05.034","article-title":"Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis","volume":"10","author":"Gotlib","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2023.04.009_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062983","article-title":"Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors","volume":"22","author":"Shomali","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856123000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856123000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:52:22Z","timestamp":1760179942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856123000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0889856123000437"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2023.04.009","relation":{},"ISSN":["0889-8561"],"issn-type":[{"type":"print","value":"0889-8561"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2023.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}